Press Room

With CMTA’s support, researchers at San Raffaele Scientific Institute in Milan, Italy, led by Alessandra Bolino, PhD, are making significant progress in developing an AAV9-based genetic therapy for CMT4B1. This $380,000 CMTA Strategy To Accelerate ...

The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at Gladstone Institutes to develop a CRISPR-based therapy for CMT2A. This CMTA Strategy To Accelerate Research (CMTA-STAR) initiative aims to create ...

CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member and clinic director of the CMTA Center of Excellence at the C. Besta Neurological Institute in Milan, Italy, Davide Pareyson, MD, and colleagues review the latest ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Joshua A. Smith, DO, as a CMTA Center of Excellence at the University of ...

The Charcot-Marie-Tooth Association (CMTA) announces a $90,860 investment in a new imaging research project at UC San Diego to study how MFN2 mutations drive CMT2A progression. This CMTA Strategy To Accelerate Research (CMTA-STAR) project will ...